STOCK TITAN

[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Black Diamond Therapeutics Director Prakash Raman acquired 5,526 shares of common stock at $2.33 per share on June 20, 2025, bringing their total direct ownership to 22,519 shares.

Key details of the transaction:

  • The shares were issued under the company's Fifth Amended and Restated Non-Employee Director Compensation Policy
  • The acquisition represents an election to receive stock in lieu of cash compensation for annual services as a non-employee director
  • The reported price is based on the closing market price of the company's common stock on June 18, 2025
  • The transaction was reported via Form 4 filing, executed by Attorney-in-Fact Brent Hatzis-Schoch

Prakash Raman, direttore di Black Diamond Therapeutics, ha acquisito 5.526 azioni ordinarie al prezzo di 2,33 $ per azione il 20 giugno 2025, portando la sua partecipazione diretta totale a 22.519 azioni.

Dettagli principali della transazione:

  • Le azioni sono state emesse secondo la Quinta Politica Modificata e Ristabilita di Compensazione per Direttori Non Dipendenti della società
  • L'acquisizione rappresenta una scelta di ricevere azioni anziché compenso in contanti per i servizi annuali come direttore non dipendente
  • Il prezzo riportato si basa sul prezzo di chiusura di mercato delle azioni ordinarie della società del 18 giugno 2025
  • La transazione è stata comunicata tramite la presentazione del Modulo 4, eseguita dall'Avvocato Delegato Brent Hatzis-Schoch

Prakash Raman, director de Black Diamond Therapeutics, adquirió 5,526 acciones comunes a $2.33 por acción el 20 de junio de 2025, elevando su propiedad directa total a 22,519 acciones.

Detalles clave de la transacción:

  • Las acciones fueron emitidas bajo la Quinta Política Enmendada y Restablecida de Compensación para Directores No Empleados de la empresa
  • La adquisición representa una elección de recibir acciones en lugar de compensación en efectivo por servicios anuales como director no empleado
  • El precio reportado se basa en el precio de cierre de mercado de las acciones comunes de la empresa el 18 de junio de 2025
  • La transacción fue reportada mediante la presentación del Formulario 4, ejecutada por el Apoderado Brent Hatzis-Schoch

Black Diamond Therapeutics의 이사 Prakash Raman이 2025년 6월 20일에 주당 $2.335,526주의 보통주를 취득하여 총 직접 보유 주식 수를 22,519주로 늘렸습니다.

거래 주요 내용:

  • 주식은 회사의 제5차 개정 및 재정비된 비임원 이사 보상 정책에 따라 발행되었습니다
  • 이번 취득은 비임원 이사로서 연간 서비스에 대한 현금 보상 대신 주식을 받기로 선택한 것입니다
  • 보고된 가격은 2025년 6월 18일 회사 보통주의 시장 마감 가격을 기준으로 합니다
  • 거래는 대리인 Brent Hatzis-Schoch에 의해 작성된 Form 4 신고서를 통해 보고되었습니다

Prakash Raman, administrateur de Black Diamond Therapeutics, a acquis 5 526 actions ordinaires au prix de 2,33 $ par action le 20 juin 2025, portant sa détention directe totale à 22 519 actions.

Détails clés de la transaction :

  • Les actions ont été émises conformément à la cinquième politique modifiée et révisée de rémunération des administrateurs non salariés de la société
  • L'acquisition représente un choix de recevoir des actions plutôt qu'une rémunération en espèces pour les services annuels en tant qu'administrateur non salarié
  • Le prix déclaré est basé sur le cours de clôture des actions ordinaires de la société au 18 juin 2025
  • La transaction a été déclarée via le dépôt du formulaire 4, exécuté par le mandataire Brent Hatzis-Schoch

Prakash Raman, Direktor von Black Diamond Therapeutics, erwarb am 20. Juni 2025 5.526 Stammaktien zu je 2,33 $ und erhöhte damit seinen direkten Gesamtbesitz auf 22.519 Aktien.

Wichtige Details der Transaktion:

  • Die Aktien wurden gemäß der fünften geänderten und neu gefassten Vergütungspolitik für nicht angestellte Direktoren des Unternehmens ausgegeben
  • Der Erwerb stellt eine Wahl dar, Aktien anstelle von Barvergütung für jährliche Dienste als nicht angestellter Direktor zu erhalten
  • Der gemeldete Preis basiert auf dem Schlusskurs der Stammaktien des Unternehmens am 18. Juni 2025
  • Die Transaktion wurde mittels Formular 4 gemeldet, ausgeführt vom Bevollmächtigten Brent Hatzis-Schoch
Positive
  • None.
Negative
  • None.

Prakash Raman, direttore di Black Diamond Therapeutics, ha acquisito 5.526 azioni ordinarie al prezzo di 2,33 $ per azione il 20 giugno 2025, portando la sua partecipazione diretta totale a 22.519 azioni.

Dettagli principali della transazione:

  • Le azioni sono state emesse secondo la Quinta Politica Modificata e Ristabilita di Compensazione per Direttori Non Dipendenti della società
  • L'acquisizione rappresenta una scelta di ricevere azioni anziché compenso in contanti per i servizi annuali come direttore non dipendente
  • Il prezzo riportato si basa sul prezzo di chiusura di mercato delle azioni ordinarie della società del 18 giugno 2025
  • La transazione è stata comunicata tramite la presentazione del Modulo 4, eseguita dall'Avvocato Delegato Brent Hatzis-Schoch

Prakash Raman, director de Black Diamond Therapeutics, adquirió 5,526 acciones comunes a $2.33 por acción el 20 de junio de 2025, elevando su propiedad directa total a 22,519 acciones.

Detalles clave de la transacción:

  • Las acciones fueron emitidas bajo la Quinta Política Enmendada y Restablecida de Compensación para Directores No Empleados de la empresa
  • La adquisición representa una elección de recibir acciones en lugar de compensación en efectivo por servicios anuales como director no empleado
  • El precio reportado se basa en el precio de cierre de mercado de las acciones comunes de la empresa el 18 de junio de 2025
  • La transacción fue reportada mediante la presentación del Formulario 4, ejecutada por el Apoderado Brent Hatzis-Schoch

Black Diamond Therapeutics의 이사 Prakash Raman이 2025년 6월 20일에 주당 $2.335,526주의 보통주를 취득하여 총 직접 보유 주식 수를 22,519주로 늘렸습니다.

거래 주요 내용:

  • 주식은 회사의 제5차 개정 및 재정비된 비임원 이사 보상 정책에 따라 발행되었습니다
  • 이번 취득은 비임원 이사로서 연간 서비스에 대한 현금 보상 대신 주식을 받기로 선택한 것입니다
  • 보고된 가격은 2025년 6월 18일 회사 보통주의 시장 마감 가격을 기준으로 합니다
  • 거래는 대리인 Brent Hatzis-Schoch에 의해 작성된 Form 4 신고서를 통해 보고되었습니다

Prakash Raman, administrateur de Black Diamond Therapeutics, a acquis 5 526 actions ordinaires au prix de 2,33 $ par action le 20 juin 2025, portant sa détention directe totale à 22 519 actions.

Détails clés de la transaction :

  • Les actions ont été émises conformément à la cinquième politique modifiée et révisée de rémunération des administrateurs non salariés de la société
  • L'acquisition représente un choix de recevoir des actions plutôt qu'une rémunération en espèces pour les services annuels en tant qu'administrateur non salarié
  • Le prix déclaré est basé sur le cours de clôture des actions ordinaires de la société au 18 juin 2025
  • La transaction a été déclarée via le dépôt du formulaire 4, exécuté par le mandataire Brent Hatzis-Schoch

Prakash Raman, Direktor von Black Diamond Therapeutics, erwarb am 20. Juni 2025 5.526 Stammaktien zu je 2,33 $ und erhöhte damit seinen direkten Gesamtbesitz auf 22.519 Aktien.

Wichtige Details der Transaktion:

  • Die Aktien wurden gemäß der fünften geänderten und neu gefassten Vergütungspolitik für nicht angestellte Direktoren des Unternehmens ausgegeben
  • Der Erwerb stellt eine Wahl dar, Aktien anstelle von Barvergütung für jährliche Dienste als nicht angestellter Direktor zu erhalten
  • Der gemeldete Preis basiert auf dem Schlusskurs der Stammaktien des Unternehmens am 18. Juni 2025
  • Die Transaktion wurde mittels Formular 4 gemeldet, ausgeführt vom Bevollmächtigten Brent Hatzis-Schoch
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Raman Prakash

(Last) (First) (Middle)
C/O BLACK DIAMOND THERAPEUTICS, INC.
ONE MAIN STREET, 14TH FLOOR

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A(1) 5,526 A $2.33(2) 22,519 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2025.
/s/ Brent Hatzis-Schoch, Attorney-in-Fact 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of BDTX stock did Director Raman Prakash acquire on June 20, 2025?

According to the Form 4 filing, Director Raman Prakash acquired 5,526 shares of BDTX common stock on June 20, 2025.

What was the price per share for BDTX Director Prakash's stock acquisition?

The shares were acquired at a price of $2.33 per share, based on the closing market price of BDTX's common stock on June 18, 2025.

Why did BDTX Director Raman Prakash receive these shares?

The shares were issued as compensation in lieu of cash payment for annual services as a non-employee director, according to BDTX's Fifth Amended and Restated Non-Employee Director Compensation Policy.

How many BDTX shares does Raman Prakash own after this transaction?

Following this transaction, Raman Prakash directly owns 22,519 shares of BDTX common stock.

What type of ownership does Raman Prakash have in these BDTX shares?

Raman Prakash has direct ownership (D) of the shares, as indicated in Column 6 of Table I in the Form 4 filing.
Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

BDTX Rankings

BDTX Latest News

BDTX Latest SEC Filings

BDTX Stock Data

139.88M
56.32M
2.7%
97.51%
13.08%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE